Carcinoma, Ovarian Epithelial: all 1,619 studies

Page 4 of 17. Open to participants first (245), then studies with results posted, then the rest; newest registration first within each.

• Metastatic Tumor Cell Trap Device in Patients With Advanced Ovarian CancerCompletedNCT03085238Not applicableResults posted
• IP ALT-803 Followed by SQ ALT-803 for Ovarian CancerCompletedNCT03054909Phase 2Results posted
• A Phase 2 Study of Kevetrin in Subjects With Ovarian CancerCompletedNCT03042702Phase 2Results posted
• IGFBP-2 Vaccine and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Undergoing SurgeryTerminatedNCT03029611Phase 2Results posted
• Phase II Study of Intraperitoneal NanoPac® in Patients With Ovarian CancerTerminatedNCT03029585Phase 2Results posted
• Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor StatusCompletedNCT02983799Phase 2Results posted
• Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian CancerTerminatedNCT02978222Phase 2Results posted
• Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian CancerCompletedNCT02915523Phase 1/2Results posted
• Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian CancerTerminatedNCT02900560Phase 2Results posted
• Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian CancerCompletedNCT02889900Phase 2Results posted
• ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer PatientsCompletedNCT02855944Phase 3Results posted
• Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT02853318Phase 2Results posted
• Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Epithelial Ovarian Cancer (EOC).TerminatedNCT02834975Phase 2Results posted
• Non-interventional European Study of Trabectedin + PLD in the Treatment of Relapsed Ovarian Cancer (ROC) PatientsCompletedNCT02825420Results posted
• Evaluation of Response to the Neoadjuvant Chemotherapy for Advanced Ovarian Cancer by Multimodal Functional ImagingCompletedNCT02792959Not applicableResults posted
• Phase II: Pembrolizumab/Carboplatin/Taxol in Epithelial Ovary CancerCompletedNCT02766582Phase 2Results posted
• TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian CancerCompletedNCT02764333Phase 2Results posted
• Role of Intraperitoneal Intraoperative Chemotherapy With Paclitaxel in the Surgical Treatment of Peritoneal Carcinomatosis From Ovarian Cancer. Hyperthermia Versus NormothermiaCompletedNCT02739698Phase 2Results posted
• A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic CancersCompletedNCT02728830Early Phase 1Results posted
• Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100)TerminatedNCT02718417Phase 3Results posted
• Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT02713386Phase 1/2Results posted
• Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian CancerCompletedNCT02657889Phase 1/2Results posted
• FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovarian CancerTerminatedNCT02641639Phase 2/3Results posted
• A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube CancerCompletedNCT02631876Phase 3Results posted
• A Study of Pembrolizumab With Standard Treatment in Patients With Recurrent Platinum-resistant Ovarian CancerCompletedNCT02608684Phase 2Results posted
• Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT02606305Phase 1/2Results posted
• A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200)CompletedNCT02580058Phase 3Results posted
• Effect of Acetylcysteine With Topotecan Hydrochloride on the Tumor Microenvironment in Patients With Persistent or Recurrent High Grade Ovarian, Primary Peritoneal, or Fallopian Tube CancerTerminatedNCT02569957Phase 2Results posted
• Phase 1/2a Two-Arm Dose-Escalation Study of BAX69 in Subjects With Malignant Ascites of Ovarian CancerTerminatedNCT02540356Phase 1/2Results posted
• Acalabrutinib (ACP-196) Alone and in Combination With Pembrolizumab in Ovarian Cancer (KEYNOTE191)CompletedNCT02537444Phase 2Results posted
• RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)CompletedNCT02489903Phase 2Results posted
• Mirena® IUD's Effect on Fallopian Tube Fimbriae and Ovarian Cortical Inclusion Cyst Cell ProliferationCompletedNCT02477202Not applicableResults posted
• To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian CancerCompletedNCT02476968Phase 4Results posted
• Carboplatin Plus Docetaxel With Day 2 Pegylated G-CSF (Neulasta®) in Patients With Advanced Stage Ovarian CarcinomaTerminatedNCT02469116Phase 2Results posted
• Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian CancerCompletedNCT02440425Phase 2Results posted
• A Study of BBI503 in Asymptomatic Recurrent Ovarian Cancer Patients With CA-125 ElevationTerminatedNCT02432690Phase 2Results posted
• Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian CancerCompletedNCT02431559Phase 1/2Results posted
• Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer PatientsCompletedNCT02421588Phase 3Results posted
• Fermented Wheat Germ Extract in Women With Ovarian CancerTerminatedNCT02411565Early Phase 1Results posted
• A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy RegimensCompletedNCT02354586Phase 2Results posted
• BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor TreatmentTerminatedNCT02326844Phase 2Results posted
• Phase 2 Study of OTL38 for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian CancerCompletedNCT02317705Phase 2Results posted
• Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal CancerCompletedNCT02311907Phase 3Results posted
• A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Participants With Low CA125 Platinum-sensitive Ovarian CancerCompletedNCT02289950Phase 2Results posted
• Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity CancerCompletedNCT02283658Phase 2Results posted
• Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum TreatmentsCompletedNCT02282020Phase 3Results posted
• Ovarian Cancer Patient-Centered Decision AidCompletedNCT02259699Not applicableResults posted
• A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate CancerTerminatedNCT02203513Phase 2Results posted
• Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT02122185Phase 2Results posted
• Photoacoustic Imaging of the OvaryTerminatedNCT02110277Not applicableResults posted
• p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246CompletedNCT02098343Phase 1/2Results posted
• Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-TreatmentTerminatedNCT02035345Phase 4Results posted
• GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian CancerTerminatedNCT02012192Phase 1/2Results posted
• A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian CancerCompletedNCT02004093Phase 2Results posted
• Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3)CompletedNCT01968213Phase 3Results posted
• Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerTerminatedNCT01962948Phase 1/2Results posted
• Trial of Pimasertib With SAR245409 or Placebo in Ovarian CancerCompletedNCT01936363Phase 2Results posted
• A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)CompletedNCT01891344Phase 2Results posted
• Salvage Ovarian FANG™ Vaccine + CarboplatinumCompletedNCT01867086Phase 2Results posted
• Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal CancerCompletedNCT01853644Phase 2Results posted
• A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal CancerTerminatedNCT01849874Phase 3Results posted
• A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian CancerCompletedNCT01847274Phase 3Results posted
• A Study to Compare CAELYX With Topotecan HCL in Patients With Recurrent Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based ChemotherapyTerminatedNCT01840943Phase 3Results posted
• A Trial of Intravenous Denileukin Diftitox Plus Subcutaneous Pegylated IFNα-2A in Stage III or IV Ovarian CancerTerminatedNCT01773889Phase 2Results posted
• Sentinel Node Detection in Clinical Early Stage Ovarian CancerCompletedNCT01734746Not applicableResults posted
• SGI-110 in Combination With Carboplatin in Ovarian CancerCompletedNCT01696032Phase 2Results posted
• Pertuzumab in Platinum-Resistant Low Human Epidermal Growth Factor Receptor 3 (HER3) Messenger Ribonucleic Acid (mRNA) Epithelial Ovarian Cancer (PENELOPE)CompletedNCT01684878Phase 3Results posted
• Birinapant for Advanced Ovarian, Fallopian Tube, and Peritoneal CancerTerminatedNCT01681368Phase 2Results posted
• BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian CancerCompletedNCT01669798Phase 2Results posted
• VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal CancerCompletedNCT01666444Phase 2Results posted
• A Study LY2228820 for Recurrent Ovarian CancerCompletedNCT01663857Phase 1/2Results posted
• Dose-finding Study in Platinum-Resistant Ovarian CancerCompletedNCT01653912Phase 1/2Results posted
• Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial CancerCompletedNCT01631552Phase 1/2Results posted
• Ovarian Cancer Vaccine for Patients Who Have Progressed During the CAN-003 StudyCompletedNCT01617629Phase 2Results posted
• Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian CancerCompletedNCT01611558Phase 2Results posted
• A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian CancerCompletedNCT01610206Phase 2Results posted
• CT Antigen TCR-redirected T Cells for Ovarian Cancer.CompletedNCT01567891Phase 1/2Results posted
• Salvage Ovarian FANG™ Vaccine + BevacizumabCompletedNCT01551745Phase 2Results posted
• Surgical Trial Comparing LIGASURE Assisted Recto-Sigmoid Resection and Omentectomy Compared to StandCompletedNCT01549925Not applicableResults posted
• Cvac as Maintenance Treatment in Patients With Epithelial Ovarian Cancer in Complete Remission Following First-line Chemotherapy or Second-line TreatmentTerminatedNCT01521143Phase 2Results posted
• Intra-op Detection of Occult Ovarian Carcinoma Using a Folate-Alpha Receptor Specific Fluorescent LigandTerminatedNCT01511055Phase 2Results posted
• A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)CompletedNCT01482715Phase 1/2Results posted
• A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian CancersCompletedNCT01447706Phase 2Results posted
• Phase II Study of Clinical Activity of Pegaspargase in Women With Relapsed or Refractory Epithelial Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal CancerCompletedNCT01313078Phase 2Results posted
• A Trial of FANG™ Vaccine for Participants With Ovarian CancerCompletedNCT01309230Phase 2Results posted
• Panitumumab and Gemcitabine in Relapsed Ovarian CancerTerminatedNCT01296035Phase 2Results posted
• Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid TumorsCompletedNCT01286987Phase 1Results posted
• Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian CancerTerminatedNCT01275664Not applicableResults posted
• A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian CancerCompletedNCT01239732Phase 3Results posted
• SJG-136 in Treating Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer That Did Not Respond to Previous Treatment With Cisplatin or CarboplatinTerminatedNCT01200797Phase 2Results posted
• Saracatinib and Paclitaxel in Platinum-resistant Ovarian CancerCompletedNCT01196741Phase 2/3Results posted
• Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian CancerCompletedNCT01196429Phase 2Results posted
• RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerCompletedNCT01175343Phase 2Results posted
• Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron OverloadTerminatedNCT01159067Phase 2Results posted
• Study of JI-101 in Patients With Advanced Low Grade Endocrine Tumors, Ovarian Cancers or K-RAS Mutant Colon CancersTerminatedNCT01149434Phase 1/2Results posted
• Neoadjuvant Therapy for Ovarian CancerCompletedNCT01146795Phase 2Results posted
• WCC# 59 Hyperthermic Intraperitoneal Chemotherapy Utilizing Carboplatin in First Recurrence Ovarian CancerTerminatedNCT01144442Not applicableResults posted
• E7080 in Combination With Carboplatin + Gemcitabine Versus Carboplatin + Gemcitabine Alone as Second Line Therapy in Patients With Platinum-Sensitive Recurrent Ovarian Cancer by CA125TerminatedNCT01133756Phase 1/2Results posted
• Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast CancerCompletedNCT01105650Phase 2Results posted
• First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube CancerCompletedNCT01097746Phase 2Results posted

← Carcinoma, Ovarian Epithelial overview